Pharmacogenetics of GLP-1 Receptor Agonists in Brazilian Admixed Populations: Polymorphisms Associated with Variability in Glycemic Response, Weight Loss, and Adverse Events

Authors

  • Jullie Ana Di Paula Matos de Sousa Centro Universitário Metropolitano da Amazônia
  • Vitor Rocha Leitão Universidade Federal do Pará
  • João Luis de Sena Figueira Centro Universitário Metropolitano da Amazônia
  • Cecília Mariana Lobo de Araújo Centro Universitário Metropolitano da Amazônia
  • Helena Corradini Rossy Centro Universitário do Estado do Pará
  • Sophya Amaral Neves Braga Centro Universitário Metropolitano da Amazônia https://orcid.org/0009-0004-7750-0983
  • Carolina Soares Chady Centro Universitário Metropolitano da Amazônia https://orcid.org/0009-0007-0731-3869
  • Lorena Elza Rêgo Ferreira Centro Universitário Metropolitano da Amazônia
  • Mário Antônio Mendes Libório Filho Centro Universitário Metropolitano da Amazônia
  • Maria Eduarda de Lima Dacier Lobato Centro Universitário Metropolitano da Amazônia
  • Alice Beatriz Lima Farias Centro Universitário Metropolitano da Amazônia
  • Alcilene Monteiro Lima Centro Universitário Metropolitano da Amazônia

DOI:

https://doi.org/10.36557/2674-8169.2026v8n2p494-515

Keywords:

GLP-1 Receptor Agonists, GLP1R Receptor, Pharmacogenetics, Genetic Polymorphism

Abstract

Introduction: GLP-1 receptor agonists are effective in type 2 diabetes and obesity but show significant interindividual variability in glycemic response, weight loss, and adverse events. In Brazilian admixed populations, the distribution of genetic variants may alter pharmacogenetic associations described in European/Asian populations. Objective: To synthesize pharmacogenetic evidence on GLP-1 receptor agonists associated with glycemic response, weight loss, and adverse events, emphasizing applicability and gaps in Brazilian admixed populations. Methodology: Narrative review in PubMed, Scopus, SciELO, and LILACS (2010–February/2026), prioritizing clinical trials, pharmacogenomic studies, systematic reviews, and Brazilian population genetics data. Qualitative thematic synthesis. Results: GLP1R is the central candidate gene, with variants such as rs6923761 showing heterogeneous associations. Studies suggest genotype-treatment interaction with liraglutide. Variants in GLP1R and pathways such as ARRB1 may modulate metabolic response and gastrointestinal adverse events, but evidence is limited. In Brazil, specific data are scarce, without robust studies controlling for local ancestry. Conclusion: Pharmacogenetics of GLP-1 receptor agonists is promising but insufficient for individual clinical decisions, especially in admixed populations. Priority agenda requires Brazilian cohorts with broad genotyping and ancestry adjustment.

Downloads

Download data is not yet available.

References

AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE FOR DIABETES. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. Diabetes Care, v. 49, n. Supplement_1, p. S183-S215, jan. 2026. DOI: https://doi.org/10.2337/dc26-S009

BERTHOLIM NASCIBEN, Aline et al. Pharmacogenomics for admixed populations: a Brazilian perspective. Frontiers in Pharmacology, v. 14, p. 1178715, 2023. DOI: https://doi.org/10.3389/fphar.2023.1178715

BOUSABA, Joelle; VOSOUGHI, Kia; DILMAGHANI, Saam; PROKOP, Larry J.; CAMILLERI, Michael. Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta analysis. Pharmacogenomics, v. 24, n. 5, p. 283-295, abr. 2023. DOI: https://doi.org/10.2217/pgs-2022-0192

CHEDID, Victor et al. A GLP 1 receptor polymorphism affects gastric emptying response to liraglutide and exenatide. Neurogastroenterology and Motility, v. 30, n. 5, p. e13313, maio 2018. DOI: https://doi.org/10.1111/nmo.13313

DAWED, Adem Y. et al. Pharmacogenomics of GLP 1 receptor agonists: a genome wide analysis of observational data and large randomised controlled trials. The Lancet Diabetes and Endocrinology, v. 11, n. 1, p. 33-41, jan. 2023. DOI: https://doi.org/10.1016/S2213-8587(22)00340-0

EGHBALI, Mohammad et al. Pharmacogenetics Study in Iranian People with Type 2 Diabetes: Liraglutide Response and GLP1R Variants. Advances in Therapy, 2024. DOI: https://doi.org/10.1007/s12325-023-02761-1

ESCHER, René et al. A new approach for assessing local ancestry and admixture dynamics in complex populations. Scientific Reports, v. 12, p. 25521, 2022. DOI: https://doi.org/10.1038/s41598-022-25521-7

FAILLIE, Jean Louis et al. Incretin Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2022. DOI: https://doi.org/10.1002/cpt.2430

FERREIRA, Mariana C. et al. Association of TCF7L2 rs7903146 polymorphism with exenatide response in Brazilian patients with type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, v. 11, 2019. DOI: https://doi.org/10.1186/s13098-019-0401-6

GERMAN, Christopher A. et al. Genetic factors associated with glycemic and weight loss responses to GLP 1 receptor agonists. Nature Medicine, 2025. DOI: https://doi.org/10.1038/s41591-025-03645-3

GERSTEIN, Hertzel C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet, v. 394, n. 10193, p. 121-130, jul. 2019. DOI: https://doi.org/10.1016/S0140-6736(19)31149-3

INTERNATIONAL DIABETES FEDERATION. IDF Diabetes Atlas 11th Edition 2025. Bruxelas: IDF, 2025. Disponível em: https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf. Acesso em: 03 fev. 2026.

JENSTERLE, Mojca et al. Short term combined treatment with liraglutide and metformin leads to significant weight loss and improvement of endocrine and metabolic parameters in obese women with polycystic ovary syndrome: a randomized trial. European Journal of Clinical Pharmacology, 2015. DOI: https://doi.org/10.1007/s00228-015-1866-1

KLEN, Jan et al. The GLP 1 Receptor Agonists: Current Evidence and Future Directions. International Journal of Molecular Sciences, v. 23, n. 7, p. 3451, 2022. DOI: https://doi.org/10.3390/ijms23073451

KRISTENSEN, Søren Lund et al. Cardiovascular, mortality, and kidney outcomes with GLP 1 receptor agonists in patients with type 2 diabetes: a systematic review and meta analysis of cardiovascular outcome trials. The Lancet Diabetes and Endocrinology, v. 7, n. 10, p. 776-785, out. 2019. DOI: https://doi.org/10.1016/S2213-8587(19)30249-9

MARSO, Steven P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). The New England Journal of Medicine, v. 375, n. 4, p. 311-322, jul. 2016. DOI: https://doi.org/10.1056/NEJMoa1603827

MARSO, Steven P. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). The New England Journal of Medicine, v. 375, n. 19, p. 1834-1844, nov. 2016. DOI: https://doi.org/10.1056/NEJMoa1607141

MASELLI, Daniel B. et al. GLP1R and TCF7L2 Genotypes Associate With the Effects of Liraglutide on Gastrointestinal Function and Weight Loss. Obesity, 2022. DOI: https://doi.org/10.1002/oby.23481

MASHAYEKHI, Mona et al. Effects of a GLP 1 receptor polymorphism on responses to liraglutide. Journal of Endocrinology, v. 267, n. 1, p. e250174, out. 2025. DOI: https://doi.org/10.1530/JOE-25-0174

MINISTÉRIO DA SAÚDE (BRASIL). Vigitel Brasil 2006-2024: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde, 2024. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2006_2024.pdf. Acesso em: 03 fev. 2026.

NUNES, Kátia et al. The genomic mosaic of Brazil. Science, 2025. DOI: https://doi.org/10.1126/science.adl3564

RATHMANN, Wolfgang; BONGAERTS, Brenda. Pharmacogenetics of novel glucose lowering drugs. Diabetologia, v. 64, n. 6, p. 1201-1212, jun. 2021. DOI: https://doi.org/10.1007/s00125-021-05402-w

REHFELD, Jens F. et al. GLP 1 receptor agonism suppresses cholecystokinin secretion and affects satiety related physiology in humans. Scandinavian Journal of Gastroenterology, 2018. DOI: https://doi.org/10.1080/00365521.2018.1509948

ROCHA, Carolina S. et al. The Brazilian Initiative on Precision Medicine, BIPMed: resources and workflows for genomic data analysis and interpretation. npj Genomic Medicine, v. 5, p. 49, 2020. DOI: https://doi.org/10.1038/s41525-020-00149-6

SUAREZ KURTZ, Guilherme. Pharmacogenomics in Brazil: challenges and opportunities. Pharmacogenomics, v. 15, n. 9, p. 1239-1245, 2014. DOI: https://doi.org/10.2217/pgs.13.238

UEDA, Peter et al. Glucagon Like Peptide 1 Receptor Agonists and Risk of Intestinal Obstruction or Ileus: a population based study. Clinical Gastroenterology and Hepatology, 2024. DOI: https://doi.org/10.1016/j.cgh.2023.08.034

WILDING, John P. H. et al. Once Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, v. 384, n. 11, p. 989-1002, mar. 2021. DOI: https://doi.org/10.1056/NEJMoa2032183

YU, Ming et al. Pharmacogenetic association of GLP1R variants with exenatide response in type 2 diabetes. Pharmacogenomics, v. 20, 2019. DOI: https://doi.org/10.2217/pgs-2018-0159

ZHENG, Zhichao et al. A comprehensive review of GLP 1 receptor biology and therapeutic targeting. Signal Transduction and Targeted Therapy, v. 9, 2024. DOI: https://doi.org/10.1038/s41392-024-01931-z.

Downloads

Published

2026-02-10

How to Cite

Sousa, J. A. D. P. M. de, Leitão, V. R., Figueira, J. L. de S., Araújo , C. M. L. de, Rossy, H. C., Braga, S. A. N., Chady , C. S., Ferreira , L. E. R., Filho , M. A. M. L., Lobato, M. E. de L. D., Farias, A. B. L., & Lima , A. M. (2026). Pharmacogenetics of GLP-1 Receptor Agonists in Brazilian Admixed Populations: Polymorphisms Associated with Variability in Glycemic Response, Weight Loss, and Adverse Events. Brazilian Journal of Implantology and Health Sciences, 8(2), 494–515. https://doi.org/10.36557/2674-8169.2026v8n2p494-515

Issue

Vol. 8 No. 2 (2026): BJIHS QUALIS B3 - FATOR DE IMPACTO SJIF 5.807 - ÍNDICE H 19

Section

Literature Review

License

Copyright (c) 2026 Jullie Ana Di Paula Matos de Sousa, Vitor Rocha Leitão, João Luis de Sena Figueira, Cecília Mariana Lobo de Araújo , Helena Corradini Rossy, Sophya Amaral Neves Braga, Carolina Soares Chady , Lorena Elza Rêgo Ferreira , Mário Antônio Mendes Libório Filho , Maria Eduarda de Lima Dacier Lobato, Alice Beatriz Lima Farias, Alcilene Monteiro Lima

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors are copyright holders under a CCBY 4.0 license.